Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 4;23(23):15284.
doi: 10.3390/ijms232315284.

Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice

Affiliations

Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice

Błażej D Pędzich et al. Int J Mol Sci. .

Abstract

Serotoninergic psychedelics such as psilocybin have been reported to elicit a long-lasting reduction in depressive symptoms. Although the main target for serotoninergic psychedelics, serotonin type 2A receptor (5-HT2A), has been established, the possible mechanism of the antidepressant action of psychedelics remains unknown. Using the mouse forced swim test model, we examined whether the administration of the synthetic serotoninergic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) would modulate 5-HT2A receptor levels in the medial prefrontal cortex (mPFC) and revert stress-induced changes in behavior. Mice subjected to swim stress developed a passive stress-coping strategy when tested in the forced swim test 6 days later. This change in behavior was not associated with the hypothesized increase in 5-HT2A receptor-dependent head twitch behaviors or consistent changes in 5-HT2A receptor levels in the mPFC. When DOI was administered 1 day before the forced swim test, a low dose (0.2 mg/kg i.p.) unexpectedly increased immobility while a high dose (2 mg/kg i.p.) had no significant effect on immobility. Nevertheless, DOI evoked a dose-dependent decrease in 5-HT2A levels in the mPFC of mice previously exposed to swim stress. Our findings do not support the hypothesis that the downregulation of 5-HT2A receptors in the mPFC contributes to the antidepressant-like properties of serotoninergic psychedelics.

Keywords: 5-HT2A; DOI; behavioral despair; downregulation; head twitch; mPFC; mice; psychedelics; stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effect of swim-stress exposure on 5-HT2A receptor-mediated behavior in mice. (A) Experimental design. Mice were exposed to 15 min forced swim stress or stayed in a home cage on day 0. On day 6, mice received a single injection of a vehicle solution (1% DMSO in saline, Con: n = 16, Str: n = 12) or DOI (low dose: 0.2 mg/kg, Con: n = 16, Str: n = 10; high dose: 2.0 mg/kg, Con: n = 16, Str: n = 10). Behavior of mice was immediately recorded for locomotor activity and head twitch assessment. (B) Total head twitch count observed for 15 min after treatment. Head twitch scores for the vehicle groups were obtained and plotted for a limited number of mice and used as a visual reference. (C) Activity measured by distance traveled. Data are represented as mean values +/− SEM.
Figure 2
Figure 2
Effect of DOI on passive stress-coping behavior in the forced swim test in mice. (A) Latency to immobility. (B) Immobility count. (C) Climbing behavior. (D) Swimming behavior. Plots represent classification of 5 s intervals. Data are represented as mean values +/− SEM. * p < 0.05 vs. Veh group.
Figure 3
Figure 3
Effects of DOI administration on 5-HT2A/PSD-95 ratio in a crude membrane fraction of the mouse mPFC. (A) Representation of a target area. (B) Representative western blot results for the 5-HT2A receptor and PSD-95 signal. (C) Quantification of 5-HT2A/PSD-95 signal ratio, normalized to control vehicle group. Data are represented as mean values +/− SEM. * p < 0.05 vs. Veh group.

Similar articles

Cited by

References

    1. Naghavi M. Global, Regional, and National Burden of Suicide Mortality 1990 to 2016: Systematic Analysis for the Global Burden of Disease Study 2016. BMJ. 2019;364:l94. doi: 10.1136/bmj.l94. - DOI - PMC - PubMed
    1. Jaffe D.H., Rive B., Denee T.R. The Humanistic and Economic Burden of Treatment-Resistant Depression in Europe: A Cross-Sectional Study. BMC Psychiatry. 2019;19:247. doi: 10.1186/s12888-019-2222-4. - DOI - PMC - PubMed
    1. McIntyre R.S., Filteau M.-J., Martin L., Patry S., Carvalho A., Cha D.S., Barakat M., Miguelez M. Treatment-Resistant Depression: Definitions, Review of the Evidence, and Algorithmic Approach. J. Affect. Disord. 2014;156:1–7. doi: 10.1016/j.jad.2013.10.043. - DOI - PubMed
    1. Nichols D.E. Psychedelics. Pharm. Rev. 2016;68:264–355. doi: 10.1124/pr.115.011478. - DOI - PMC - PubMed
    1. Carhart-Harris R.L., Goodwin G.M. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. 2017;42:2105–2113. doi: 10.1038/npp.2017.84. - DOI - PMC - PubMed

LinkOut - more resources